Miki Ando

723 total citations
65 papers, 453 citations indexed

About

Miki Ando is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Miki Ando has authored 65 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Genetics and 17 papers in Hematology. Recurrent topics in Miki Ando's work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers). Miki Ando is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers). Miki Ando collaborates with scholars based in Japan, United States and India. Miki Ando's co-authors include Jun Ando, Hiromitsu Nakauchi, Kazuo Oshimi, Makoto Sasaki, Koichi Sugimoto, Motoki Egashira, Toshiyuki Kitoh, Sheldon M. Schuster, Norio Komatsu and Midori Ishii and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Oncogene.

In The Last Decade

Miki Ando

52 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miki Ando Japan 12 233 152 151 130 47 65 453
Juying Wei China 12 212 0.9× 105 0.7× 81 0.5× 75 0.6× 19 0.4× 44 380
Robert Touitou France 8 324 1.4× 296 1.9× 115 0.8× 110 0.8× 17 0.4× 15 637
Paola Zancai Italy 13 269 1.2× 242 1.6× 89 0.6× 217 1.7× 19 0.4× 18 516
Isacco Ferrarini Italy 12 118 0.5× 77 0.5× 82 0.5× 104 0.8× 21 0.4× 30 301
Toshina Ishiguro‐Oonuma Japan 9 208 0.9× 234 1.5× 68 0.5× 39 0.3× 50 1.1× 26 569
Svenja Debey‐Pascher Germany 14 152 0.7× 272 1.8× 305 2.0× 61 0.5× 10 0.2× 18 697
Sandra Schamus United States 12 434 1.9× 395 2.6× 151 1.0× 84 0.6× 31 0.7× 12 782
Reshmi Parameswaran United States 13 178 0.8× 219 1.4× 243 1.6× 23 0.2× 9 0.2× 27 525
Erika M. Cook United States 9 106 0.5× 150 1.0× 224 1.5× 75 0.6× 7 0.1× 18 433
Daniel H. Li United States 10 194 0.8× 71 0.5× 99 0.7× 90 0.7× 9 0.2× 12 417

Countries citing papers authored by Miki Ando

Since Specialization
Citations

This map shows the geographic impact of Miki Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miki Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miki Ando more than expected).

Fields of papers citing papers by Miki Ando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miki Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miki Ando. The network helps show where Miki Ando may publish in the future.

Co-authorship network of co-authors of Miki Ando

This figure shows the co-authorship network connecting the top 25 collaborators of Miki Ando. A scholar is included among the top collaborators of Miki Ando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miki Ando. Miki Ando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shirane, Shuichi, et al.. (2025). Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution. International Journal of Hematology. 122(3). 458–461. 1 indexed citations
2.
Takaku, Tomoiku, Naoki Watanabe, Noriyoshi Iriyama, et al.. (2025). Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia. International Journal of Hematology.
3.
4.
Ishii, Midori, Takaharu Kimura, Tomoyuki Yamaguchi, et al.. (2024). Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. Cancer Research Communications. 4(3). 723–737. 7 indexed citations
5.
6.
Araki, Yoshihiko, Maki Fujishiro, Shigeki Tomita, et al.. (2023). Possible New Histological Prognostic Index for Large B-Cell Lymphoma. Journal of Clinical Medicine. 12(19). 6324–6324. 3 indexed citations
7.
Ishii, Midori, et al.. (2023). iPSC-Derived CD4 T Cell Generation and Investigation of CD4/CD8 T Cell Lineage Choice. Blood. 142(Supplement 1). 2071–2071. 3 indexed citations
8.
Morishita, Soji, Yoshinori Hashimoto, Tomonori Ochiai, et al.. (2023). Impact of non‐driver gene mutations on thrombo‐haemorrhagic events in ET patients. British Journal of Haematology. 204(1). 221–228. 2 indexed citations
9.
Tokuhira, Michihide, Yuta Kimura, Takayuki Tabayashi, et al.. (2023). Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. International Journal of Hematology. 118(2). 210–220. 1 indexed citations
10.
Ishii, Midori, Jun Ando, Kazuya Ikeda, et al.. (2023). iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer. Cell Reports Medicine. 4(12). 101327–101327. 10 indexed citations
11.
Takaku, Tomoiku, Naoki Watanabe, Noriyoshi Iriyama, et al.. (2023). Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice. Internal Medicine. 62(22). 3299–3303. 1 indexed citations
12.
Sato, Ai, et al.. (2023). Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis. Experimental Hematology. 130. 104132–104132. 1 indexed citations
13.
Yasuda, Hajime, Naoko Kaga, Hikari Taka, et al.. (2023). Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology. 93(3). 265–268.
14.
Yasuda, Hajime, Yuji Tomizawa, Makoto Sasaki, et al.. (2022). Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon. 8(10). e10928–e10928. 8 indexed citations
15.
Yasuda, Hajime, Makoto Sasaki, Tomoiku Takaku, et al.. (2022). Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin. SHILAP Revista de lepidopterología. 15(1). 263–266. 3 indexed citations
16.
Ishii, Midori, Jun Ando, Satoshi Yamazaki, et al.. (2021). iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma. Cancer Immunology Research. 9(10). 1175–1186. 17 indexed citations
17.
Ando, Jun, Midori Ishii, Yoichiro Mitsuishi, et al.. (2021). SCLC-J1, a novel small cell lung cancer cell line. Biochemistry and Biophysics Reports. 27. 101089–101089. 4 indexed citations
18.
Ando, Miki, Jun Ando, Midori Ishii, et al.. (2021). Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. Molecular Therapy. 30(2). 534–549. 29 indexed citations
19.
Sugimoto, Koichi, Makoto Sasaki, Yasushi Isobe, et al.. (2007). Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene. 27(22). 3091–3101. 21 indexed citations
20.
Tamayose, Kenji, Koichi Sugimoto, Miki Ando, & Kazuo Oshimi. (2002). Mononucleosis syndrome and acute monocytic leukemia. European Journal Of Haematology. 68(4). 236–238. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juying Wei Breakdown of academic impact, for papers by Robert Touitou Breakdown of academic impact, for papers by Paola Zancai Breakdown of academic impact, for papers by Isacco Ferrarini Breakdown of academic impact, for papers by Toshina Ishiguro‐Oonuma Breakdown of academic impact, for papers by Svenja Debey‐Pascher Breakdown of academic impact, for papers by Sandra Schamus Breakdown of academic impact, for papers by Reshmi Parameswaran Breakdown of academic impact, for papers by Erika M. Cook Breakdown of academic impact, for papers by Daniel H. Li
Rankless by CCL
2026